证券代码：603392 证券简称：万泰生物 公告编号：2025-045 北京万泰生物药业股份有限公司 关于公司九价人乳头瘤病毒疫苗（大肠埃希菌） 首次获得批签发证明的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司（以下简称"公司"）全资子公司厦门 万泰沧海生物技术有限公司生产的九价人乳头瘤病毒疫苗（大肠埃希菌）（以下简 称"九价 HPV 疫苗"）获得中国食品药品检定研究院签发的《生物制品批签发证 明》。现将相关情况公告如下： 一、药品基本信息 产品名称：九价人乳头瘤病毒疫苗（大肠埃希菌） 编 号：批签中检 20252249 生产企业：厦门万泰沧海生物技术有限公司 审批结论：予以签发。 二、对公司的影响 随着九价 HPV 疫苗产品首次获得批签发证明，标志着公司的该产品正式投放市 场，这将进一步丰富和优化公司的产品梯队，为公司形成新的收入和利润增长点， 增强公司盈利能力和市场竞争能力，强化公司的市场地位。同时公司九价 HPV 疫苗 与在售二价 HPV 疫苗的组合，将构建起差异化且极具竞争力 ...

公告称，随着九价HPV疫苗产品首次获得批签发证明，标志着公司的该产品正式投放市场，这将进一步 丰富和优化公司的产品梯队，为公司形成新的收入和利润增长点，增强公司盈利能力和市场竞争能力， 强化公司的市场地位。 智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限 公司生产的九价人乳头瘤病毒疫苗(大肠埃希菌)(以下简称"九价HPV疫苗")获得中国食品药品检定研究 院签发的《生物制品批签发证明》。 ...

Core Viewpoint - Wantai Biological's financial performance in the first half of 2025 shows significant declines in revenue and profit, indicating potential challenges for the company moving forward [1]. Financial Performance Summary - In the first half of 2025, Wantai Biological achieved operating revenue of 844 million yuan, a decrease of 38.25% year-on-year [1][3]. - The net profit attributable to shareholders was -144 million yuan, down 155.30% from 260 million yuan in the same period last year [1][3]. - The net profit excluding non-recurring gains and losses was -243 million yuan, a decline of 481.93% compared to 63.5 million yuan in the previous year [1][3]. - The net cash flow from operating activities was -66.55 million yuan, compared to 129 million yuan in the same period last year, representing a decrease of 151.77% [1][3]. Previous Year Comparison - In 2024, Wantai Biological reported operating revenue of 2.245 billion yuan, a decline of 59.25% year-on-year [3]. - The net profit attributable to shareholders was 106 million yuan, down 91.49% from the previous year [3]. - The net profit excluding non-recurring gains and losses was -186 million yuan, compared to 1.078 billion yuan in the same period last year [3]. - The net cash flow from operating activities was 355 million yuan, a decrease of 76.91% year-on-year [3]. Company Background - Wantai Biological was listed on the Shanghai Stock Exchange on April 29, 2020, with an initial public offering of 43.6 million shares at a price of 8.75 yuan per share [4]. - The total funds raised in the IPO amounted to 382 million yuan, with a net amount of 318 million yuan after expenses [4]. - The company has utilized the raised funds for various projects, including automation technology upgrades and international certification for its products [4].

Core Viewpoint - The company has released its 2025 semi-annual report, detailing its financial performance and management of raised funds, while ensuring compliance with relevant regulations and transparency in operations [1][5][20]. Group 1: Company Overview - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is engaged in the development and production of vaccines and biological products [2]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [2]. Group 2: Financial Data - The total amount raised from a non-public offering in June 2022 was approximately RMB 349,999.99 million, with a net amount of RMB 346,015.57 million after deducting related expenses [20]. - As of June 30, 2025, the remaining balance of raised funds was RMB 150,940.25 million, including RMB 23,025.20 million in dedicated accounts and RMB 127,915.05 million in principal-protected financial products [21][22]. Group 3: Fund Management - The company has established a dedicated fund management system, ensuring that raised funds are stored in special accounts and managed in compliance with regulations [23][24]. - The company has signed tripartite supervision agreements with banks and its sponsor to ensure the proper use of raised funds [24][25]. Group 4: Fund Utilization - In the first half of 2025, the company directly invested RMB 19,132.35 million into projects funded by the raised capital [21]. - The company has not terminated any new fundraising investment projects during the reporting period [30]. Group 5: Impairment Provisions - The company has recognized a total impairment provision of RMB 8,085.62 million for the first half of 2025, which includes credit impairment losses of RMB 5,743 million and inventory impairment losses of RMB 2,342.62 million [42][44]. - The increase in credit impairment losses is attributed to delayed payments from local disease control centers due to financial constraints [41]. Group 6: Investor Communication - The company plans to hold a semi-annual performance briefing on September 2, 2025, to address investor inquiries and provide insights into its financial results [35][36].

Group 1 - The core point of the article is that Wantai Biological (603392) reported a significant decline in revenue and a net loss for the first half of 2025, primarily due to challenges in its vaccine segment [2] - The company achieved an operating revenue of 844 million yuan, representing a year-on-year decrease of 38.25% [2] - The net profit attributable to shareholders was -144 million yuan, indicating a shift from profit to loss compared to the previous year [2] Group 2 - The decline in revenue is attributed to market adjustments, government procurement policies, and the expansion of the age range for the nine-valent HPV vaccine, which led to lower-than-expected sales [2]

证券日报网讯 8月20日晚间，万泰生物发布公告称，公司第六届监事会第九次会议审议通过了《2025年 半年度报告全文及其摘要》《关于公司2025年半年度募集资金存放与实际使用情况的专项报告的议 案》。 （编辑 任世碧） ...

证券日报网讯 8月20日晚间，万泰生物发布公告称，公司第六届董事会第九次会议审议通过了《2025年 半年度报告全文及其摘要》《关于公司2025年半年度募集资金存放与实际使用情况的专项报告的议 案》。 （编辑 任世碧） ...

Growth - SOTONG Development reported a net profit of 523 million yuan in the first half of the year, a year-on-year increase of 1568.52% [2] - Muyuan Foods achieved a net profit of 10.53 billion yuan, reflecting a year-on-year growth of 1169.77% [2] - Spring Autumn Electronics posted a net profit of 93.32 million yuan, up 248.44% year-on-year [2] - Baobian Electric's net profit reached 75.37 million yuan, marking a year-on-year increase of 230.76% [2] - Baiyun Airport reported a net profit of 750 million yuan, with a year-on-year growth of 71.32% [2] - Hengdian East Magnetic's net profit was 1.02 billion yuan, showing a year-on-year increase of 58.94% [2] - China XD Electric recorded a net profit of 598 million yuan, up 30.08% year-on-year [2] - Heng Rui Medicine achieved a net profit of 4.45 billion yuan, reflecting a year-on-year growth of 29.67% [2] - Yanjinpuzi reported a net profit of 373 million yuan, with a year-on-year increase of 16.7% [2] - Lizhu Group posted a net profit of 1.281 billion yuan, marking a year-on-year growth of 9.4% [2] Decline and Loss - Zhongheng Electric reported a net profit of 47.48 million yuan, a year-on-year decline of 30.19% [2] - Yonghui Supermarket experienced a net loss of 241 million yuan, transitioning from profit to loss year-on-year [2] - Wantai Biological Pharmacy reported a net loss of 144 million yuan, also transitioning from profit to loss year-on-year [2] - Jimin Health reported a net loss of 52.70 million yuan [2]

（文章来源：证券日报） 证券日报网讯 8月20日晚间，万泰生物发布公告称，公司计划于2025年9月2日上午11：00-12：00举行 2025年半年度业绩说明会。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月20日，万泰生物发布公告称，2025年上半年实现营业 收入8.44亿元，同比下降38.25%；归属于上市公司股东的净利润为亏损1.44亿元，同比下降155.3%；归 属于上市公司股东的扣除非经常性损益的净利润为亏损2.43亿元，同比下降481.93%。 ...